Evidence map›Paper›PMID 41083638›Full record

ArticleDoklady. Biochemistry and biophysics2025

A Syngenic Mouse Model of Breast Cancer Expressing Human ERBB2 and NanoLuc Luciferase Genes.

E I Shramova, S M Deyev, G M Proshkina

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

E I ShramovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. shramova.ei@gmail.com.
S M DeyevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
G M ProshkinaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syngeneic models are widely used in experimental oncology both for modeling tumor diseases and for testing anticancer drugs. However, when testing targeted drugs aimed at human tumor-associated antigens, the presence of target antigens in the animal's body is important. In this study, a syngeneic cell line with stable expression of two genes-the ERBB2 gene encoding human epidermal growth factor receptor type 2 (HER2) and the NanoLuc luciferase gene-was created based on murine mammary gland carcinoma. Optical bioimaging methods have proven that the created cell line is characterized by stable expression of ERBB2 and NanoLuc in vitro and in vivo, retains the aggressive growth of the original 4T1 cell line in animals, and forms spontaneous metastases that are detected in the animal's body by intravital biovisualization methods.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesLuciferasesMammary Neoplasms, ExperimentalAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLuciferasesERBB2HER2NаnoLuсoptical bioimagingsyngeneic modeltumor-associated antigen

Identifiers

PMID41083638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.